Hyperoxia Before and After Cardiac Arrest and Myocardial Damage

Hyperoxia Before and After Cardiac Arrest and Myocardial Damage, a Retrospective Cohort Study

Several studies show how patients with hyperoxia after cardiac arrest has increased mortality, but the association of hyperoxia before cardiac arrest and myocardial damage has never been investigated. Neither has the association between hyperoxia after cardiac arrest and myocardial injury.

Our research hypothesis is that hyperoxia before cardiac arrest aggravates myocardial damage, secondly we wish to analyze the association between hyperoxia after cardiac arrest and myocardial injury.

The exposure variables is oxygenation within 48 hours before and 48 hours after cardiac arrest, our primary outcome is myocardial damage and will be measured as peak troponin within 30 days after cardiac arrest.

Study Overview

• Status: Completed
• Conditions: Cardiac Arrest
• Intervention / Treatment: Other: Oxygenation

• Study Type: Observational
• Enrollment (Actual): 163

Contacts and Locations

Study Locations

• Denmark
  • Copenhagen, Denmark, 2400
    • Bispebjerg Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Patients with in hospital cardiac arrest, who had return of spontaneus circulaiton and was then admitted to ICU in a hospital in the Capital Region of Denmark.

Description

Inclusion Criteria:

• 18 years or older
• With a record of ICD-10 diagnosis of cardiac arrest in 2014, admitted to a hospital in the Capital Region of Denmark.
• First recorded cardiac arrest in 2014
• Admitted to ICU
• Serum troponin measured within 7 days after cardiac arrest

Exclusion Criteria:

• Out of hospital cardiac arrest, OHCA
• In of hospital cardiac arrest, IHCA, but with no registered saturation before cardiac arrest.

Study Plan

How is the study designed?

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Hypoxia; Defined as a group of patients with oxygen saturation <94 % irrespective of supplemental oxygen. If COPD, defined as oxygen saturation <88 % irrespective of supplemental oxygen.	Other: Oxygenation; Oxygenation measured as oxygen supply and saturation before cardiac arrest, and oxygenation measured as PaO2 after cardiac arrest.
Normoxia; Defined as a group of patients with oxygen saturation 94 % - 98 % in combination of supplemental oxygen, or oxygen saturation >94 % without supplemental oxygen. If COPD, defined as oxygen saturation 88 % - 92 % in combination of supplemental oxygen, or oxygen saturation >88 % without supplemental oxygen.	Other: Oxygenation; Oxygenation measured as oxygen supply and saturation before cardiac arrest, and oxygenation measured as PaO2 after cardiac arrest.
Hyperoxia; Defined as a group of patients with oxygen saturation >98 % in combination of supplemental oxygen. If COPD, defined as oxygen saturation >92 % in combination of supplemental oxygen.	Other: Oxygenation; Oxygenation measured as oxygen supply and saturation before cardiac arrest, and oxygenation measured as PaO2 after cardiac arrest.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Peak troponin within 30 days after cardiac arrest	Troponin measurements on patients after cardiac arrest.	30 days

Secondary Outcome Measures

Outcome Measure	Time Frame
30-day and 1-year mortality	Up to 1 year.
Troponin area under the curve within 3 days after cardiac arrest	3 days
Length of ICU stay after cardiac arrest	through study completion,on average of 4-8 weeks.
Length of hospital stay after cardiac arrest	through study completion,on average of 4-8 weeks.

Collaborators and Investigators

• Sponsor: University Hospital Bispebjerg and Frederiksberg

Study record dates

Study Major Dates

• Study Start (ACTUAL): May 30, 2018
• Primary Completion (ACTUAL): August 10, 2018
• Study Completion (ACTUAL): September 30, 2018

Study Registration Dates

• First Submitted: June 4, 2018
• First Submitted That Met QC Criteria: June 17, 2018
• First Posted (ACTUAL): June 27, 2018

Study Record Updates

• Last Update Posted (ACTUAL): October 23, 2018
• Last Update Submitted That Met QC Criteria: October 20, 2018
• Last Verified: October 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Signs and Symptoms, Respiratory; Heart Arrest; Hyperoxia
• Other Study ID Numbers: HyperoxiaandCardiacarrest

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No